| RNA splicing as a therapeutic target in myelodysplastic syndromes |
|
Seminars in Hematology |
Myelodysplastic Syndromes (MDS) |
| Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape |
|
Immunotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Consensus recommendations for severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
